Products Blinatumomab for Injection
Blinatumomab for Injection Phase 1 UNKNOWN 💤 Quiet Interest: 25/100
Pediatric ALL, B Cell, Minimal Residual Disease
Feb 18, 2022 → Dec 1, 2024
About Blinatumomab for Injection Blinatumomab for Injection is a phase 1 stage product being developed by Amgen for Pediatric ALL, B Cell. The current trial status is unknown. This product is registered under clinical trial identifier NCT04604691. Target conditions include Pediatric ALL, B Cell, Minimal Residual Disease.
What happened to similar drugs? 3 of 19 similar drugs in Pediatric ALL, B Cell were approved
Clinical Trials (1) NCT ID Phase Status Start Completion Indication NCT04604691 Phase 1 UNKNOWN Feb 18, 2022 Dec 1, 2024 Pediatric ALL, B Cell
Product Company Stage Hype Score Ramucirumab Eli Lilly Phase 1 erlotinib + etoposide Astellas Pharma Phase 2 Mitoxantrone Hydrochloride Liposome + Irinotecan + Vincristine Sun Pharmaceutical Phase 1 Perampanel Oral Suspension + Perampanel Tablet Eisai Phase 2 Eribulin Mesylate Eisai Phase 1 Decitabine + Decitabine Eisai Phase 2 Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily Sumitomo Pharma Phase 1 Remimazolam Tosilate for injection + Propofol Injection Jiangsu Hengrui Medicine Phase 2/3 Ceftaroline fosamil + Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam + Cephalexin or Clindamycin or Linezolid AstraZeneca Phase 2/3 candsartan cilexetil AstraZeneca Phase 3 Durvalumab / Tremelimumab Combination Therapy AstraZeneca Phase 1/2 Rotavirus Vaccine Merck Pre-clinical basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent) + MMF, cyclosporine, steroids Novartis Phase 3 VAL489 + VAL489 matching placebo Novartis Phase 3 LCZ696 + Enalapril + Placebo of LCZ696 + Placebo of Enalapril + LCZ696 Novartis Phase 2/3 Everolimus Novartis Phase 2 Corticosteroids + Cyclosporine + mycophenolate mofetil Roche Phase 2 Entecavir + Lamivudine + Pegylated Interferon Alfa-2A Roche Phase 3 Etanercept Amgen Phase 3 Denosumab Amgen Phase 3